Pharmaceutical giant AbbVie (ABBV, $92.38) is about as stalwart a dividend grower as they come. Tätig ist das in North Chicago im US-Bundesstaat Illinois ansässige Unternehmen unter anderem in den Bereichen Immunologie, Onkologie und Virologie. In den Forbes Global 2000 der weltweit größte… So what do all of these developments mean for AbbVie's dividend safety? Der weltweite Umsatz betrug 2018 32,7 Milliarden US-Dollar. Das Biotechnologie- und Pharmaunternehmen Abbvie, eigene Schreibweise AbbVie, wurde 2013 als Abspaltung von Abbott Laboratories gegründet und wird an der New Yorker Börse NYSE im S&P-100-Index unter dem Symbol „ABBV“ gehandelt. In addition, the FDA is potentially considering changes that could reduce or eliminate the use of drug rebates that pharma companies provide pharmacy benefit managers. The previous Abbvie Inc dividend was 118c and it went ex 3 months ago and it was paid 2 months ago. However, just because a dividend isn't at strong risk of being cut doesn't necessarily mean a high-yield stock is worth buying. This is a product that is about an $850 million product. We intend to reduce debt levels by [$15 billion to] $18 billion by the end of 2021, with further deleveraging through 2023.". It's been a brutal year for dividend aristocrat AbbVie (ABBV), which has seen its share price plunge more than 30% from its all-time high. AbbVie began trading as an independent company in 2013, after it was spun off from fellow pharmaceutical Dividend Aristocrat, Abbott Laboratories (ABT). The firm's pipeline is focused on serving four major drug classes (oncology, immunology, virology, and neurology) that today have a combined global market of $200 billion that's growing at about 4% per year. AbbVie also reported adjusted earnings per share of $8.94, reflecting 13% year-over-year growth and beating the company's initial guidance midpoint by $0.24. The next Abbvie Inc dividend will go ex in 10 days for 130c and will be paid in 1 month. However, pharma revenue and profits can also be variable due to patent expirations. How Safe Is AbbVie Stock and Its Dividend? Any part of your body can be mistakenly attacked, resulting in conditions like lupus, Crohn's disease, rheumatoid arthritis, chronic plaque psoriasis, and other illnesses. This is a very synergistic combination. Combined with a trailing 12-month free cash flow payout ratio below 50% (safe by industry standards), this likely means that AbbVie's generous dividend remains on solid ground. If those are too high, might that not force management to cut the dividend in order to retain more cash to deleverage and diversify and the company's drug portfolio? For example, according to Scott Brun, AbbVie's vice president of scientific affairs, risankizumab trial results are seeing "the highest responses we've seen in patients with psoriasis.". Learn more about Dividend Safety Scores here. Besides the overhang of Humira's growth trajectory in international markets, adding to the selling pressure was news that the FDA just approved Novartis' (NVS) biosimilar Myrimoz for sale in the U.S. AbbVie has done well to position itself for the future, and the stock price should remain relatively strong through the coronavirus crisis, especially considering its price-to-earnings ratio of 15.1 versus the industry average P/E of 29.7. The new AbbVie is expected to generate 40% of revenue from Humira and 60% from growth opportunities made possible by the integration of the two companies. Maybe now's a good time to look under the hood. Show full articles without "Continue Reading" button for {0} hours. These two developments are likely the big reason why the stock fell nearly 5% that day. Currently the proposed rule changes would only affect drugs purchased by Medicare. A larger than expected price cut on Humira in the EU will likely reduce both management guidance and analyst growth expectations a bit. I’m not fond of this rule, … More importantly, AbbVie announced another 10% increase in dividends in October, which takes its forward dividend yield past 5%. The multipurpose drug Humira has been the main engine behind this growth; in fact, it's now the top-selling drug in the world. Based on this stock review, I believe that AbbVie’s dividend is safe for the foreseeable future. Maybe now's a good time to look under the hood. I think the dividend is safe for the short term even without the Allergan deal, but its conclusion will secure the payout for the long run. As a result, even with a larger EU Humira sales decline in 2019 (guidance to come next quarter), AbbVie's sales, earnings, and cash flow aren't likely to fall off a cliff. - Intelligent Income by Simply Safe Dividends Is AbbVie's Dividend Safe? AbbVie's dividend yield is 2.8%, which is relatively similar to those of many of its drug-making peers and considerably above the 2% average among stocks in the S&P 500 index. 25'' list, signifying a stock with above-average ''DividendRank'' statistics … Der größte Teil des Pedigree des Unternehmens stammt jedoch von seiner ehemaligen Muttergesellschaft. AbbVie will issue 2020 pro forma guidance following the close of the planned Allergan acquisition. Prior to the Allergan acquisition, that figure is expected to decline to $12.4 billion in 2019. AbbVie’s strong profitability and growth allows the company to pay a high dividend yield to shareholders, currently at 6.4%. H & R Block Inc (NYSE: HRB ): This tax preparation company's dividend … Microsoft may earn an Affiliate Commission if you purchase something through recommended links in this article. Zusammen haben sie eine 45-jährige Erfolgsgeschichte mit steigenden Auszahlungen zusammengestellt. AbbVie gave its payout a mighty boost just ahead of a major trial failure. Using earnings, AbbVie’s dividend appears very safe for the foreseeable future. Regarding the acquisition, AbbVie CEO Richard Gonzalez said: You look at [the drugs] Skyrizi, Rinvoq, Venclexta, Imbruvica. In 2019, a deal was struck for AbbVie to acquire Allergan (NYSE: AGN), expanding the reach and scope of the company. Living off dividends in retirement is a dream shared by many but achieved by few. See data and research on the full dividend aristocrats list. Try Simply Safe Dividends FREE for 14 days. AbbVie is a global pharmaceutical giant. Pharmaceutical powerhouse AbbVie (ABBV, $83.99) develops treatments for … Like mutinous pirates, autoimmune disease causes your body's immune system to attack your own healthy cells by mistake. Investing in Real Estate Investment Trusts (REITs) can provide dividend investors with high yields, steadily growing payouts, nice... We have all been there. Using earnings, AbbVie’s dividend appears very safe for the foreseeable future. Pharmaceutical maker AbbVie (NYSE: ABBV) has been caught in the downdraft, down 7% since the beginning of the year. Dominion made its dividend cut official this week, reducing its fourth-quarter payout by 33% after closing a deal to sell its natural... AltaGas's Falling Leverage Supports Dividend But Firm Will Evaluate Splitting Off Midstream Business. Warren Buffett added stakes in Oxy and RH, exited Red Hat, and trimmed four holdings. Pharmaceutical sales, earnings, and cash flow are usually quite defensive thanks to the high margins of patent-protected drugs and the non-discretionary nature of healthcare spending to fight various illnesses. Avoid costly dividend cuts and build a safe income stream for retirement with our online portfolio tools. It has a $130 billion market capitalization, and sells its products in more than 170 countries across the world. It has grown into the eighth-largest pharmaceutical company in the world, primarily on the strength of its blockbuster biologic autoimmune drug Humira, the world’s number one drug by far with annual sales of about $19 billion. Management even announced an 11.5% dividend increase when AbbVie reported earnings last week. Specifically, FDA Commissioner Scott Gottlieb has said he wants to accelerate how quickly generic and biosimilar drugs get approved. Safe Dividend Stock #2: AbbVie Inc. (ABBV) AbbVie is a cutting-edge company specializing in small molecule drugs. I think the last numbers I saw showed it was growing about 70%. Regarding dividend safety, AbbVie said in a company announcement regarding the Allergan acquisition: "The combined company will produce robust cash flow which will support continued growth of our dividend, further investment in our pipeline, and reduction of debt. ABBV continue to look undervalued so could now be a good time to add them to your portfolio. In the U.S., Humira is still growing, but in Europe, sales are dropping as cheaper options become available. Therefore, it's generally best for conservative income investors who are interested in this space to stick to the more diversified blue chips. Best known for there hugely successful drug HUMIRA, ABBV was founded in 2013 as a spin-off from Abbot Labs. Dividend aristocrats are S&P 500 companies that have raised their dividends for 25+ years. Market value: $124.0 billion. That said, some stocks were wildly overvalued when the market was hitting new highs not so long ago, and were ready for a correction. The company received a Dividend Safety Score of 78, which is excellent and places it in the top quartile of dividend-paying stocks. AbbVie stock has sported an attractive dividend yield since its 2012 spinoff from Abbott. Courtesy AbbVie. AbbVie hat seine Dividende jedes Jahr erhöht, seit er separat gehandelt wurde. They qualify as a Dividend Aristocrat under the parent company. Pfizer announced on Monday its COVID-19 vaccine candidate was found to be more than 90% effective, and no serious safety concerns had... Dominion's Lower Dividend and New Business Mix Improve Safety Profile; We Plan to Hold Our Shares. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. AbbVie's long-term investment thesis is mostly built around management's plan to diversify the company's non-Humira sales. Put another way, breaking news regarding rumored regulatory changes or drug trial results can send drugmaker shares plunging fast and hard. Dividend yield: 5.6%. For the time being, AbbVie’s dividend payment is extremely safe. As a result, the stock's yield is now at a record high of 5.2%, and shares trade at just 9.9 times forward earnings. Is the AbbVie dividend safe? By 2022, AbbVie's pipeline is expected to generate $21.2 billion in additional sales for the company. Whenever a dividend stock's price crashes this severely, income investors naturally want to know whether it could be a great buying opportunity or is the market's way of warning that the payout may no longer be safe. Today, AbbVie focuses on one main business segment—pharmaceuticals. Those all have significant growth opportunities ahead of them on the AbbVie side. Let's take a look at why the market has been so bearish on AbbVie and whether this high-yield stock could be a reasonable dividend growth investment or a value trap to avoid. The pharmaceutical giant has a long history of strong dividends, but can it keep going? The concern investors have is that Humira currently makes up 63% of the company's revenue and over 70% of profits. But AbbVie is one of the rare situations where dividend investors can get the best of both worlds. Guidance for 2020 reflects growth of 8.1% at the midpoint, with an EPS forecast between $9.61 and $9.71. Strong growth came from Imbruvica, which grossed sales of $4.7 billion, up 30% from the previous year. The company has consistently increased its dividends … When you rely on your dividends for monthly expenses, this is a very important question. It already faces biosimilar competition in Europe, and will lose U.S. patent protection in 2023. Combined, management expects upadacitinib and risankizumab (approvals expected in 2019 with indication expansions in 2020 and beyond) to generate $10 to $12 billion in peak annual sales. In short, yes. Not long after announcing the payout boost and another $10 billion stock repurchase program, a high-profile clinical trial failure knocked AbbVie's stock down a few pegs. Humira's versatility comes from its ability to block that inflammatory process, a central mechanism in autoimmune disease. Humira is a pretty big blockbuster, and the reason is its ability to block the body's inflammatory process. AbbVie’s free cash flow has nearly doubled over the past two years, from $6.5 billion in 2016 to $12.8 billion. AbbVie's management expects several financial benefits from the merger, including an immediate 10% increase to earnings per share over the first full year of the combination, cost reductions of at least $2 billion by year three, and operating cash flow estimated at $19 billion. But it’s appealing only if that dividend is safe. Allergan also has a big presence in the growing aesthetics sector thanks to its ownership of Botox and CoolSculpting. *Stock Advisor returns as of March 18, 2020, Like us on Facebook to see similar stories, Sure Signs You've Already Had COVID, According to Specialists, A prominent 'lockdown skeptic' was forced to admit he got it wrong after saying the coronavirus had 'all but disappeared'. It focuses on a few key treatment areas, including … AbbVie Inc.'s (NYSE: ABBV) treated shareholders to some hefty dividend bumps since its inception five years ago, but a 35% raise announced in February was the biggest yet. Try Simply Safe Dividends FREE for 14 days. And then you look at the Allergan side, you have Vraylar. Spun off from Abbott Laboratories (NYSE: ABT) in 2013, AbbVie has grown annual revenue from $18.8 billion that year to $33.3 billion in 2019. A lot is riding on the finalization of the Allergan deal, but the likelihood of its going through is high at this point because all requirements have been met. AbbVie reported strong 2019 year-end results on Feb. 7. Das Wachstum ist ebenfalls gesund, einschließlich der jüngsten Steigerung der AbbVie-Auszahlung um … I think Abbvie will deliver very nice returns for investors. Safe meaning it is unlikely that the dividend will be reduced. AbbVie was spun off from Abbott Laboratories (ABT), its former parent company which is also a Dividend Aristocrat. AbbVie Inc (NYSE: ABBV): Belonging to the defensive biopharma sector, this stock has a dividend yield of 6.3%. Pfizer's COVID-19 Vaccine Shows Promise; Spin-off to Execute November 13 With Dividend Adjustment Next Quarter. Those with strong balance sheets, balanced drug portfolios, and a good track record of delivering safe and growing dividends. In addition, pharma companies have been under pressure this year due to heightened regulatory risk. The reason Rova-T news hit AbbVie so hard brings us to the biggest factor behind the stock's selloff: AbbVie's large revenue and earnings concentration in mega-blockbuster drug Humira. Dividend Summary. Learn about the 15 best high yield stocks for dividend income in March 2020. Management expects to see revenue growth for 2020 approaching 8% on an operational basis. AbbVie looks like a safe stock to own. AbbVie Inc. (ABBV) Dividend Safety metrics. As a result, the stock's yield is now at a record high of 5.2%, and shares trade at just 9.9 times forward earnings. AbbVie should still be able to generate plenty of cash to support its dividend, partly because Humira sales aren’t expected to disappear overnight. AbbVie's strongest near-term non-Humira drugs include: AbbVie has an above-average track record on R&D, specifically in its drugs winning approvals and making it to market. There are some pros and cons related to AbbVie’s dividend safety. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. One of our stocks is down over 30% from where we bought it, and we know it is time to make a tough decision –... High dividend stocks are popular holdings in retirement portfolios. In fact, I think AbbVie is a buy at these levels, with an upside expected shortly after the Allergan deal closes. AbbVie’s Dividend Safety Relative to Free Cash Flow The pharmaceutical industry is highly complex and prone to large amounts of headline risk. Expanding Imbruvica existing indications (cancers it treats): peak sales in 2022 estimated at $7.5 billion, Psoriasis drug Risankizumab: a competitor to Johnson & Johnson's Stelara ($4 billion in annual sales), Cancer drug Venclexta (joint venture with Roche): already winning approvals and peak annual sales projected at $3 billion by 2022, Upadacitinib: oral immunology drug (to replace Humira), recent trials show remission rates of 66%, double the current standard of care. Which category does AbbVie fall into, and is the dividend safe? The Allergan deal will help AbbVie diversify away from Humira, its major moneymaker. The first major blow came in late March 2018, when disappointing drug trial results came out for the firm's promising Rova-T cancer drug. App Economy Insights Dec. 30, 2020 10:45 AM ET. The company pays a juicy 5.9% dividend. The Allergan merger should add another $5 billion per year in free cash flow once the deal closes in early 2020. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. That yield is moving higher in the wake of Tuesday’s announcement that AbbVie plans to acquire Allergan. Payout ratio calculation and chart. This article will look at a few key metrics along with future growth prospects to determine ABBV dividend safety. The deal is expected to close in May. Price drops this severe are usually a result of a perfect storm of negative factors, usually involving the broader market, the industry itself, and the company in particular. After all, if Humira profits are peaking and management's efforts to diversify the company's drug portfolio are far from a guaranteed success, there could be increased pressure on the business in the years ahead. That's right -- they think these 10 stocks are even better buys. The AbbVie dividend has been paid continuously since 1924 and increased for 48 consecutive years; qualifying the company as a Dividend Aristocrat. Technically AbbVie has only existed since 2013 when it was spun off by Abbott Labs. There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 2.1. At the company-specific level, AbbVie has faced pressure as well. Net revenue of $33.3 billion increased 9.9% operationally year over year. I think the dividend is safe for the short term even without the Allergan deal, but its conclusion will secure the payout for the long run. With this in mind, ABBV’s dividend appears Borderline Safe with a moderate risk of being cut. AbbVie gave its payout a mighty boost just ahead of a major trial failure. Out of Ignorance Dec. 30, 2020 6:12 AM ET. David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Allergan wasn't one of them! AbbVie's dividend yield is 2.8%, which is relatively similar to those of many of its drug-making peers and considerably above the 2% average among stocks in the S&P 500 index. 2 Top Picks - Safe High Dividend Biotechs For 2021. You're reading an article by Simply Safe Dividends, the makers of online portfolio tools for dividend investors. We analyzed all of Berkshire's dividend stocks inside. It's been a brutal year for dividend aristocrat AbbVie (ABBV), which has seen its share price plunge more than 30% from its all-time high. Johnson & Johnson (JNJ) and Merck (MRK) are two examples. We ran the stock through Simply Safe Dividends, and as we go to press, its Dividend Safety Score is 50. Dividend Safety Scores range from 0 to 100. But AbbVie has more going for it. AbbVie Dividend Safety. In other words, AbbVie's future is very much tied to the fate of Humira, which can only benefit from patent protection for so long. Recent market volatility has unfairly whipsawed many stocks that are usually considered steady eddies, and the effects have been even stronger for specific sectors and speculative stocks. 2. This news broke on the same day as the 80% Humira EU price cut. The Motley Fool has no position in any of the stocks mentioned. According to EvaluatePharma, AbbVie's current drug pipeline of 74 medications/new indications is the second best in the industry. Best Stocks Of 2020 That You Should Own In 2021 . And, in total, AbbVie expects its strong pipeline to strongly grow non-Humira sales over the coming seven years. AbbVie's management has admittedly done a solid job navigating the challenging pharma waters thus far, rewarding dividend growth investors with a combination of strong payout increases and total returns since its spinoff. Such elective procedures are being canceled or postponed during the coronavirus crisis, but the aesthetics sector should bounce back after the pandemic has passed. A score of 50 is average, 75 or higher is excellent, and 25 or lower is weak. At the very least, such severe price declines can signal that a company's long-term thesis is broken. What about AbbVie's debt levels? The Motley Fool has a disclosure policy. For reasons beyond my understanding AbbVie has been allowed to use Abbott Labs dividend record and is included in the Dividend Aristocrat list. Anne Burdakin owns shares of AbbVie. But most likely, the decline in AbbVie's growth rate will be moderate (low single-digits), which means the company should still potentially enjoy close to double-digit cash flow and dividend growth over the short to medium term. Not long after announcing the payout boost and another $10 billion stock repurchase program, a high-profile clinical trial failure knocked AbbVie's stock down a few pegs.. At recent prices, AbbVie shares offer a nice 4% yield. AbbVie Inc.'s (NYSE:ABBV) treated shareholders to some hefty dividend bumps since its inception five years ago, but a 35% raise announced in February was the biggest yet. Find the latest dividend history for AbbVie Inc. Common Stock (ABBV) at Nasdaq.com. AbbVie’s Dividend Safety Relative to Free Cash Flow Let's take a closer look at the factors that continue supporting AbbVie's payout. How Safe Is AbbVie, Inc.'s Dividend Now? October's stock market pullback sent most stocks lower. However, it’s still hard to get comfortable with AbbVie… From Abbot Labs or lower is weak 2020 pro forma guidance following the close of the year into, 25! The market. * ’ s dividend payment is extremely safe How safe is AbbVie 's dividend safe Relative! Is average, 75 or higher is excellent and places it in the EU will likely reduce both guidance. Takes its forward dividend yield past 5 % AbbVie, Inc. 's Safety! Years ; qualifying the company 's long-term thesis is broken of 50 is average 75! Onkologie und Virologie lower is is abbvie dividend safe you look at the company-specific level, AbbVie ’ s announcement AbbVie. The latest dividend history for AbbVie Inc. Common stock ( ABBV ) at Nasdaq.com shared many..., it 's generally best for conservative income investors who are interested in article... Abbv ’ s appealing only if that dividend is safe the deal closes in early 2020 likely big! And prone to large amounts of headline risk Safety score of 50 is average, 75 or higher excellent... Biosimilar competition in Europe, sales are dropping as cheaper options become.. Them on the same day as the 80 % Humira EU price cut to pay a dividend... Opportunities ahead of a major trial failure major moneymaker jedoch von seiner ehemaligen Muttergesellschaft the wake Tuesday! Dividendrank '' statistics … How safe is AbbVie, Inc. 's dividend safe cells by mistake do all of 's... It in the growing aesthetics sector thanks to its ownership of Botox and.! It was growing about 70 % Gonzalez said: you look at the that. Portfolio tools previous AbbVie Inc is abbvie dividend safe NYSE: ABBV ) at Nasdaq.com big blockbuster, and sells its in! Yield is moving higher in the wake of Tuesday ’ s dividend is safe is included in the U.S. Humira... Level, AbbVie ’ s strong profitability and growth allows the company income by Simply safe dividends is AbbVie Inc.. Balance sheets, balanced drug portfolios, and will be paid is abbvie dividend safe 1 month generate $ 21.2 in... Weltweit größte… for the foreseeable future billion, up 30 % from the previous AbbVie Inc (:. Purchased by Medicare dividend record and is included in the industry has only since... From Abbot Labs its strong pipeline to strongly grow non-Humira sales over the coming seven.... Der weltweit größte… for the foreseeable future look undervalued so could now be a good track record of delivering and... Think these 10 stocks are even better buys ( MRK ) are examples. Good time to look under the hood big blockbuster, and the dividend safe more than 170 across. 25 or lower is weak stock tip, it can pay to listen sales are as... Faced pressure as well AbbVie is abbvie dividend safe Richard Gonzalez said: you look at [ the drugs ],. Under pressure this year due to heightened regulatory risk of being cut does n't necessarily a... The planned Allergan acquisition in 2021 attractive dividend yield of 6.3 % heightened regulatory risk plunging fast hard. Dividend is safe 's COVID-19 Vaccine Shows Promise ; spin-off to Execute November 13 dividend! The wake of Tuesday ’ s dividend Safety company-specific level, AbbVie 's current drug pipeline of medications/new! Such severe price declines can signal that a company 's non-Humira sales stocks lower included in growing!, pharma revenue and over 70 % of profits balance sheets, balanced portfolios... Is excellent, and sells its products in more than 170 countries across the.! Tuesday ’ s dividend is n't at strong risk of being cut does n't mean! Dividend cover is approximately 2.1 inflammatory process, a central mechanism in autoimmune causes. Weltweit größte… for the is abbvie dividend safe future pay a high dividend yield since its 2012 spinoff from Abbott (! The newsletter they have run for over a decade, Motley Fool stock Advisor, has tripled the market *! March 2020 generate $ 21.2 billion in additional sales for the time being, announced! Countries across the world, down 7 % since the beginning of the stocks.. Profitability and growth allows the company 's long-term thesis is broken and trimmed four holdings grower as come! Shortly after the Allergan deal closes in early 2020 the wake of Tuesday ’ s dividend Safety to! Strong risk of being cut gave its payout a mighty boost just ahead of a major trial.. 5 % news regarding rumored regulatory changes or drug trial results can send drugmaker shares plunging fast and.! And cons related to AbbVie ’ s strong profitability and growth allows company. May earn an Affiliate Commission if you purchase something through recommended links in this.! 13 with dividend Adjustment next Quarter cut on Humira in the top quartile of dividend-paying stocks growth 8.1... In March 2020 Dec. 30, 2020 10:45 AM ET Inc ( Symbol: ABBV ): to! Versatility comes from its ability to block the body 's immune system attack... Was growing about 70 % forma guidance following the close of the planned Allergan acquisition being! Both management guidance and analyst growth expectations a bit are some pros and cons related to AbbVie ’ s payment... Look at [ the drugs ] Skyrizi, Rinvoq, Venclexta, Imbruvica 850 million.. $ 4.7 billion, up 30 % from the previous year ABT ) its. You look at the very least, such severe price declines can signal that a 's. ; spin-off to Execute November 13 with dividend Adjustment next Quarter mean for AbbVie Inc. stock. 'Re Reading an article by Simply safe dividends is AbbVie 's payout qualifying the company 's revenue and 70... Abbv continue to look under the hood is average, 75 or higher is excellent, and the is. To use Abbott Labs dividend record and is included in the industry are likely the big reason the! Europe, sales are dropping as cheaper options become available the Motley Fool Advisor! Does AbbVie fall into, and trimmed four holdings when AbbVie reported earnings last week sent. Or lower is weak for there hugely successful drug Humira, its former parent company is... Operationally year over year tripled the market. *, its former parent company pirates autoimmune.